The team also announced the closure of the FA-ICD portal. Continue reading
Category Archives: AZBio News
Calviri Announces Completion of Groundbreaking Preventative Canine Cancer Vaccine Trial
PHOENIX, June 3, 2024 /PRNewswire/ — Calviri, Inc. announced the successful conclusion of the Vaccine Against Canine Cancer Study (VACCS) on May 4, 2024; a five-year clinical trial investigating a novel preventative cancer vaccine in dogs. This multi-center, double-blind, placebo-controlled study, the largest of its kind in veterinary oncology, represents a significant milestone in the fight against canine cancer.Continue reading
AZBioPEERS: IP Essentials
This insightful pre-recorded webinar on intellectual property is tailored for life science startups and presented by Jason Jardine, AZBio board member and partner at Knobbe Martens. Continue reading
Flinn Foundation-sponsored study identifies three bioscience growth areas to advance innovation and economic growth in greater Phoenix
Precision oncology/medicine, digital health, translational neurosciences to advance Phoenix Bioscience Core, new hubsContinue reading
C-Path’s Parkinson’s Consortium Supports Groundbreaking Research Utilizing Smartwatches to Monitor Disease Progression
TUCSON, Ariz., June 12, 2024 — Critical Path Institute (C-Path) today announced a new publication on how the use of wearable technology can optimize measuring symptoms important to people with Parkinson’s disease. The newly published manuscript in npj Parkinson’s Disease highlights a multistakeholder initiative consisting of collaborators from around the world coming together to share knowledge, data and resources to ask how new technologies can help to monitor people living with Parkinson’s in new ways.
C-Path’s AI Collaborations Accelerate Drug Development, Improve Lives
TUCSON, Ariz., June 12, 2024 — Critical Path Institute (C-Path) today announced the publication of a new peer-reviewed paper in the journal Clinical and Translational Science. As the preeminent leader in public-private partnerships to accelerate drug development, the paper highlights how C-Path’s AI collaborations are revolutionizing drug development, with specific advancements in the management and treatment of Type 1 Diabetes (T1D) and Parkinson’s Disease (PD). This study affirms the Institute’s commitment to using artificial intelligence (AI) and digital health technologies (DHTs) to expedite the delivery of life-saving treatments.
In Memoriam: Jack Kavanagh, co-founder of AzMN
John Thomas (Jack) Kavanagh, co-founder of the Arizona Myeloma Network (AzMN), passed away on Saturday, May 25, 2024 at the age of 87. Diagnosed with Multiple Myeloma in 1991, Jack had a successful business career prior to retiring to Arizona in 2003 and creating AzMN with his wife Barbara in 2004.
Continue reading
Anuncia Medical Announces First Successful US Implant of the Company’s ReFlow™ Device with Sonolucent Cranial Plate to Noninvasively Visualize Flushing of Hydrocephalus Shunts
Johns Hopkins First in the Country to Implant Novel FDA-Cleared Devices in Tandem for the Treatment of Pseudotumor CerebriContinue reading
UArizona launches website to match entrepreneurs and investors with high-potential, high-tech opportunities
Tech Launch Arizona StartupHub facilitates connections for venture-ready inventors seeking qualified co-founders.Continue reading